<u>Cite this as</u>: Qiong ZHAO, Luwen ZHANG, Qiufen HE, Hui CHANG, Zhiqiang WANG, Hongcui CAO, Ying ZHOU, Ruolang PAN, Ye CHEN. Targeting *TRMT5* suppresses hepatocellular carcinoma progression via inhibiting the HIF-1α pathways[J]. Journal of Zhejiang University Science B, 2023, 24(1): 50-63. http://doi.org/10.1631/jzus.B2200224

Targeting *TRMT5* suppresses hepatocellular carcinoma progression via inhibiting the HIF-1α pathways

Key words: tRNA methyltransferase 5; Hepatocellular carcinoma; Hypoxia-inducible factor 1α

Research Summary

This study mainly concentrated on the function and molecular mechanism of TRMT5 on HCC progression in the following areas:

- TRMT5 expression levels in tumor and normal liver tissues of HCC patients.
- Effect of TRMT5 on HCC progression in vitro and in vivo.
- Roles of TRMT5 on energy metabolism in HCC cells.
- RNA sequencing and HIF-1α signaling pathway.
- Effect of TRMT5 on the drug susceptibility to HCC cells.

Innovation points

- TRMT5 was upregulated in HCC and correlated with poor prognosis.
- Knockdown of TRMT5 inhibited HCC progression both in vitro and in vivo.
- Silenced TRMT5 inhibited HCC progression by preventing HIF-1α stabilization.
- Inhibition of TRMT5 sensitized HCC to doxorubicin.

Innovation points

TRMT5 regulates hepatocellular carcinoma progression via the HIF-1 α pathways.

- Fig 1 TRMT5 was upregulated in HCC and this correlated with poorer overall survival.
- Fig 2 Knockdown of TRMT5 inhibited cell proliferation and cell cycle progression in HCC cells.
- Fig 3 TRMT5 deficiency-induced metabolic reprogramming in HCC cells.
- Fig 4 Knockdown of TRMT5 inhibited both the migration and invasion of HCC cells *in vitro*.
- Fig 5 | Silencing TRMT5 suppressed HCC progression and metastasis in vivo.
- Fig 6 Knockdown of TRMT5 blocks the HIF-1 signaling pathway through increasing the cellular oxygen content.
- Fig 7 Inhibition of TRMT5 sensitizes HCC to doxorubicin by adjusting HIF-1α stabilization.